GP方案动静脉联合化疗与静脉化疗治疗晚期非小细胞肺癌的临床研究

Clinical analysis on GP regimen vein chemotherapy and combination chemotherapy of artery and vein treating advanced non small cell lung cancer

①目的观察吉西他滨联合顺铂方案分别通过动静脉联合化疗和单独静脉化疗对晚期非小细胞肺癌的疗效和毒副反应。②方法 63例晚期非小细胞肺癌随机分为GP(GEM+C-DDP)方案动静脉联合化疗组31例和单纯静脉化疗组32例。63例均完成2个周期以上化疗,统计各组有效率和1年生存率。③结果 GP方案动静脉联合化疗组有效率为58.1%,静脉化疗组有效率为34.4%,而1年生存率两组分别为70.9%、56.3%,两组间有效率有明显差异,而1年生存率无明显差异。主要不良反应为骨髓抑制及消化道反应,骨髓抑制两组间无明显差异,而消化道反应静脉组明显高于动静脉联合组。④结论 GP方案对非小细胞肺癌疗效确切。GP方案动静脉联合组比单纯静脉组近期有效率更高。

Objective To observe the effect and toxicity of gemicitabine and cisplatin（GP） regimen treating advanced non small cell lung cancer（NSCLC） by vein chemotherapy and combination chemotherapy of artery and vein.Methods Advanced NSCLC of 63 cases were divided into combination by arterial and venous group（31cases） and venous group（32cases） randomly.Two cycle chemotherapy was completed in each patient.The effective rate（CR＋PR） and 1 year survival rate were calculated finally.Results The effective rate was 58.1% in arterial and venous group,34.4% in venous group respectively and there was significant difference（P〈0.05）between two groups,while 1 year survival rate were 70.9% and 56.3% respectively but there was no significant difference（P〉0.05）.The major toxicities were bone marrow suppression and gastrointestinal toxicity,and there was no significant difference in the former between two groups（P〉0.05）,but there was significant difference in the later（P〈0.05）,which was higher in venous group than that in arterial and venous group.Conclusion GP regimen was definitely effective in NSCLC patients.The recent effective rate in combination artery and venous group was higher than that in venous group.